✦ LIBER ✦

Dose Escalation to Target Volumes of Helical Tomotherapy for Pancreatic Cancer in the Phase 1-2 Clinical Trial

✍ Scribed by Xia, T.; Chang, D.; Wang, Y.; Li, J.; Wu, W.; Zhu, F.

Book ID: 122653356
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 46 KB
Volume: 87
Category: Article
ISSN: 0360-3016
DOI: 10.1016/j.ijrobp.2013.06.795

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Is Hypofractionated (Chemo) radiation De

Is Hypofractionated (Chemo) radiation Delivered With Helical Tomotherapy a Feasible Option to Escalate the Dose in Locally-Advanced Inoperable NSCLC?: Results From a Phase 2 Trial

✍ Arcangeli, S.; Monaco, A.; Caruso, C.; Cianciulli, M.; Boboc, G.; Dognini, J.; R 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Toxicity report of a phase 1/2 dose-esca

Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy

✍ Samuel Bral; Michaël Duchateau; Harijati Versmessen; Douwe Verdries; Benedikt En 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views

Predictors of Rectal Tolerance Observed

Predictors of Rectal Tolerance Observed in a Dose-Escalated Phase 1-2 Trial of Stereotactic Body Radiation Therapy for Prostate Cancer

✍ Kim, D.W. Nathan; Cho, L. Chinsoo; Straka, Christopher; Christie, Alana; Lotan, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 677 KB

A phase 1/2, dose-escalation trial of de

A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis

✍ Pradyumna Phatak; Pierre Brissot; Mark Wurster; Paul C Adams; Herbert L. Bonkovs 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 391 KB 👁 1 views

Hereditary hemochromatosis (HH) is characterized by increased intestinal iron absorption that may result in iron overload. Although phlebotomy is widely practiced, it is poorly tolerated or contraindicated in patients with anemias, severe heart disease, or poor venous access, and compliance can vary

Activity and safety of ODM-201 in patien

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

✍ Fizazi, Karim; Massard, Christophe; Bono, Petri; Jones, Robert; Kataja, Vesa; Ja 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 465 KB

Imatinib mesylate for targeting the plat

Imatinib mesylate for targeting the platelet-derived growth factor β receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer—A dose-escalation Phase I trial

✍ Salah-Eddin Al-Batran; Akin Atmaca; Eberhard Schleyer; Claudia Pauligk; Christia 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB

## Abstract ## BACKGROUND. In previous experimental models, because of its ability to inhibit the activity of platelet‐derived growth factor β receptor, imatinib decreased the interstitial fluid pressure and improved the delivery and efficacy of anticancer drugs, including fluorouracil. The object